Related Experiment Video

Updated: Aug 15, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 15, 2011

Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor

K Sugimura1, T Ohno, S Fukuda

  • 1Institute of Immunological Science, Hokkaido University, Sapporo, Japan.

Cancer Research
|January 15, 1990
PubMed

Insights

Lymphocyte blastogenesis inhibitory factor (LBIF) effectively inhibits diverse tumor cell proliferation, acting through cytotoxic or cytostatic mechanisms. This immunoregulatory molecule shows broad-spectrum anti-tumor activity, suggesting potential therapeutic applications.

Area of Science:

  • Immunology
  • Cell Biology
  • Oncology

Background:

  • Lymphocyte blastogenesis inhibitory factor (LBIF) is recognized for its role in regulating T-lymphocyte proliferation.
  • Understanding the broader effects of LBIF on various cell types is crucial for its therapeutic potential.

Purpose of the Study:

  • To investigate the in vitro effects of purified LBIF on the proliferation of 18 different tumor cell lines.
  • To compare the anti-proliferative efficacy of LBIF against other known cytokines like interferons and tumor necrosis factor.

Main Methods:

  • Purification of LBIF using fast protein liquid chromatography (FPLC).
  • In vitro proliferation assays using 18 diverse tumor cell lines.
  • Comparative analysis with interferon-alpha, interferon-gamma, tumor necrosis factor-alpha, transforming growth factor-beta 1, and interleukin 1 alpha/beta.

Main Results:

  • LBIF demonstrated potent inhibition of proliferation across a wide range of tumor cell lines, regardless of their origin or species.
  • The anti-proliferative effects were mediated by either cytotoxic or cytostatic mechanisms, varying with the specific tumor cell line.
  • LBIF exhibited a broader spectrum of activity compared to the other cytokines tested.
  • Insensitivity in five cell lines suggests the involvement of specific LBIF receptor molecules.

Conclusions:

  • LBIF possesses significant anti-proliferative activity against a broad array of tumor cell lines.
  • The molecule's efficacy suggests a potential role in cancer therapy, warranting further investigation into its mechanisms and receptor interactions.
  • LBIF may be a key regulator of cell growth with implications for cancer treatment strategies.

More Related Videos

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs08:13

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs

Published on: December 27, 2016

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.